Drug intelligence / Profile preview

SRNDO-03

Development stage: Preclinical
Lead developer: Sirius Therapeutics
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics

Overview

SRNDO-03 is a pre-clinical small interfering RNA (siRNA) therapeutic candidate being developed by Sirius Therapeutics for the treatment of obesity. The drug is part of a pipeline of RNA-based therapies that leverage the company's proprietary delivery technology to target specific tissues, including the liver, adipose tissue, heart, kidney, and the central nervous system (CNS). While the specific molecular target of SRNDO-03 remains undisclosed, the therapy aims to modulate metabolic pathways through gene silencing. It is currently in the IND-enabling/pre-clinical phase of development.

Beyond the preview

Go deeper on SRNDO-03.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SRNDO-03.

Explore the full profile